newsfilter
← Latest News
GlobeNewswire·

Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates

Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027 Positive STENO1 safety data strengthens benefit-risk profile for ZYNQUISTA® NDA resubmission Phase 1 clinical development of LX9851